SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : T/FIF, a New Plateau
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (585)7/29/2001 11:09:13 PM
From: hmpa  Read Replies (1) of 2243
 
Degussa is very good, including process development side. I tend to think their "own" process would be better than the one they got from MCLS (and certainly cheaper in development costs - the world's most expensive way to develop a process is to outsource it to somebody like AMRI, and by extension, MCLS). Thus, for Degussa relationship with Medichem is more of a marketing advantage (customer sees a smooth transition from medicinal chemistry through kilo lab to the full scale production) rather than technological necessity. As long as there is a lot of excess cGMP production capacity for small molecules, fine chemical companies would enter whatever alliances it takes to fill it.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News